Hospital Stocks Rally Up to 5% as Centre Moves to Cap Cancer Drug Margins at 30%

Listed hospital chains staged a relief rally on Friday after reports that the government plans to cap trade margins on cancer medicines at 30% of the maximum retail price. Shares of Fortis Healthcare, Apollo Hospitals, Max Healthcare and Yatharth Hospital gained as much as 5% in morning trade, reversing part of a slide that had built up over several weeks.

What the government is planning

According to reports citing PTI, the Centre has decided to cap trade margins on all non-scheduled anti-cancer drugs at 30% of MRP. The measure is expected to cover 110 medicines, including 35 patented drugs, and could be implemented later this month.

The National Pharmaceutical Pricing Authority (NPPA) has reportedly cleared the proposal in principle using its powers under Paragraph 19 of the Drug Price Control Order, 2013, which allows it to intervene on prices in extraordinary circumstances. An expert committee under the Directorate General of Health Services is expected to finalise the list of covered drugs by October 14, after which the NPPA would issue a formal notification.

A trade margin is the gap between the price at which a drug leaves the manufacturer for a distributor or retailer and the price the patient finally pays. Cancer drugs, especially branded and patented ones, often carry very wide margins, and a large share is dispensed through in-house hospital pharmacies. The Ministry of Chemicals and Fertilizers expects the cap to cut prices of some medicines by as much as 70%.

Why hospital stocks went up, not down

At first glance, a squeeze on drug margins looks bad for hospitals. The market reaction reflects how much uncertainty had already been priced in. Apollo, Max and Fortis had fallen roughly 5-10% over recent weeks as investors waited to learn how far the government would go. Max Healthcare alone fell about 4% on Thursday.

A defined 30% ceiling gave analysts something concrete to model. Goldman Sachs estimates that oncology medicines contribute less than 5% of hospital revenue and roughly 2-2.5% of EBITDA, with slightly higher exposure for Max Healthcare and Fortis. Jefferies also described the likely earnings impact as manageable, though both flagged some near-term margin pressure. Other estimates put the potential hit to earnings for hospital chains in a range of 2% to 10%, depending on how widely the cap is applied.

The pharma angle

Drugmakers with large oncology portfolios, such as Sun Pharma and Dr Reddy's, were also in focus. For them, the effect depends on how much of their domestic revenue comes from the affected products and how much margin they currently leave with the distribution chain.

This is not the first time India has used this tool. In 2019, the NPPA capped trade margins on 42 anti-cancer drugs at up to 30%, a move that sharply lowered retail prices for several therapies.

What comes next

The final list of drugs, the effective date and the precise scope are still to be notified, and any of these could change before the NPPA's order. For patients, the measure could make long, expensive cancer treatments noticeably cheaper. For investors, the next trigger is the October 14 list and whether it stays close to what has been reported.

This is an original summary based on public reporting. See our editorial policy for how we source, write, and correct our stories.